Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Compsn. contg. neohesperidin dihydrochalcone for preventing or treating elevated blood lipid and glucose level-reated diseases

A technology of hesperidin dihydrochalcone and blood sugar level, which is applied in the functional food or beverage composition for treating such diseases, neohesperidin dihydrochalcone. field, able to address issues such as toxicity

Inactive Publication Date: 2001-10-17
KOREA RES INST OF BIOSCI & BIOTECH
View PDF0 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although many drugs have been developed for patients with non-insulin-dependent hyperglycemia, these drugs are still ineffective and relatively toxic

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compsn. contg. neohesperidin dihydrochalcone for preventing or treating elevated blood lipid and glucose level-reated diseases
  • Compsn. contg. neohesperidin dihydrochalcone for preventing or treating elevated blood lipid and glucose level-reated diseases
  • Compsn. contg. neohesperidin dihydrochalcone for preventing or treating elevated blood lipid and glucose level-reated diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Additionally, percentages of solids in solid mixtures, percentages of liquids in liquids, and percentages of solids in liquids given below are based on wt / wt, vol / vol, and wt / vol, respectively, and unless otherwise specified, all reactions are at room temperature conduct. Example 1: Toxicity of Oral Administration of Neohesperidin Dihydrochalcone

[0034] Twelve 7-week-old specific pathogen-free ICR female mice, 6 female mice weighing approximately 25-29 g each, and 6 male mice weighing approximately 34-38 g each were maintained at a temperature of 22 ± 1°C, relative humidity 55±5% and photoperiod 12L / 12D. Feed (Cheiljedang Co., mouse and rat feed) and water were sterilized and fed to the mice.

[0035] Neohesperidin dihydrochalcone purchased from Aldrich-Sigma Chemical Co. (St.Louis, MO, U.S.A) was dissolved in 0.5% Tween 80 to a concentration of 100 mg / ml, and the solution was orally administered to mice, The dosage is 0.2ml / 20g mouse body weight. The solution was...

Embodiment 2

[0037] diet group

[0038] Within 6 weeks, the rats were allowed to eat the designated food and water freely, the daily intake was recorded, and the rats were weighed every 7 days, and then the records were analyzed. All rats showed normal growth rates, with no significant differences between the two groups in terms of food intake and weight gain. (Step 2) Determination of total cholesterol, HDL-cholesterol and neutral lipid content in blood

[0039] The effect of administration of neohesperidin dihydrochalcone to rats on plasma cholesterol and neutral lipid levels was determined as follows.

[0040] Group

[0041] It can be seen from Table 2 that the total plasma cholesterol level in the neohesperidin dihydrochalcone group was 15% lower than that in the control group. In addition, the neutral lipid content of the neohesperidin dihydrochalcone group was 9% lower than that of the control group. Example 3: The activity of neohesperidin dihydrochalcone in i...

Embodiment 3

[0042] To determine the effect of feeding neohesperidin dihydrochalcone on the activity of ACAT in rats, microsomes were isolated from ready-to-use liver tissue as the enzyme source.

[0043] Each 1g of liver from each group of rats in Example 2 was mixed in 5ml of homogenization medium (0.1MKH 2 PO 4 , pH7.4, 0.1mM EDTA and 10mM β-mercaptoethanol) homogenized. The homogenate was centrifuged at 3000xg and 4°C for 15 minutes, and the supernatant thus obtained was centrifuged at 15000xg and 4°C for 15 minutes to obtain a supernatant. The supernatant was put into an ultracentrifuge tube (Beckman) and centrifuged at 100000xg and 4°C to obtain a microsomal pellet, which was then suspended in 3 ml of homogenization medium and centrifuged at 100000xg and 4°C for 1 Hour. The resulting pellet was suspended in 1 ml of homogenization medium. The protein concentration in the resulting suspension was determined by the Lowry method and adjusted to 4-8 mg / ml. The resulting suspension wa...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A pharmaceutical composition for treating or preventing an elevated blood lipid or glucose level-related disease such as hyperlipidemia, arteriosclerosis, angina pectoris, stroke, hepatic diseases and hyperglycemia in a mammal, which comprises an effective amount of neohesperidin dihydrochalcone as an active ingredient together with a pharmaceutically acceptable carrier, and a functional food or beverage composition for such a disease, which comprises an effective amount of neohesperidin dihydrochalcone.

Description

field of invention [0001] The present invention relates to a pharmaceutical composition for treating or preventing diseases associated with elevated blood lipid and blood sugar levels in mammals, such as hyperlipidemia, arteriosclerosis, angina pectoris, stroke, liver disease and hyperglycemia, the composition comprising an effective amount of Neohesperidin dihydrochalcone as an active component and a pharmaceutically acceptable carrier; the present invention also relates to a functional food or beverage composition for treating such diseases, which includes an effective amount of neohesperidin dihydrochalcone Hydrochalcone. Background of the invention [0002] It has been reported that blood lipids, especially cholesterol and triglycerides, are closely related to various diseases such as coronary heart and circulation diseases, such as arteriosclerosis and hypercholesterolemia, and fatty liver. Cholesterol, a fatty sterol is a blood lipid produced in the liver from saturat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A23C9/13A21D2/14A21D2/18A21D13/00A21D13/08A23C9/152A23C19/093A23F3/14A23G1/00A23G1/30A23G3/00A23G3/34A23G4/00A23G9/32A23G9/34A23G9/44A23G9/52A23L1/30A23L2/04A23L2/38A23L2/52A23L7/109A23L13/40A23L23/00A23L27/30A23L27/60A23L35/00A61K31/70A61K31/7028A61K31/7034A61P1/16A61P3/06A61P3/10A61P9/10C07H15/203C12G3/00
CPCA21D2/181A23G9/34A23L1/2366A23L2/52A23L1/3002A23C9/152A23L27/36A23L33/105A61P1/16A61P3/06A61P3/10A61P9/10A23L2/04A61K31/70
Inventor 卜成海郑泰淑裴基焕朴镛福崔明淑文锡植权容国李恩淑玄柄和崔良圭李哲浩李世峰朴永培金孝洙
Owner KOREA RES INST OF BIOSCI & BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com